Extracellular Secretion System Could Solve Industry Endonuclease Production Challenges

Biopharmaceutical manufacturers face challenges when producing endonuclease enzymes in large quantities using traditional E. coli systems. These enzymes are crucial for digesting unwanted DNA and RNA released during cell lysing, but they also pose a risk by degrading the host's genetic material. Professor Ramakrishna Vadde, from Yogi Vemana University in Andhra Pradesh, India, explains that expressing recombinant endonucleases in E. coli is difficult due to the enzymes' natural role in growth and survival of the bacteria.

Overexpression of these proteins can also lead to cellular issues such as protein aggregation and reduced protein folding, making the production process technically demanding and costly. Vadde suggests that using an expression system that secretes the endonucleases outside the cell could be a solution. The research presents a proprietary secretion-based platform called BacSec that directs the recombinant nuclease out of the host cell's cytoplasm, minimizing the risk of intracellular nucleic acid degradation.

This approach reduces contamination risk, simplifies purification, and improves product recovery, leading to lower production costs and a reduction in goods sold (COGs). Extracellular secretion also helps promote proper protein folding, eliminating the need for complex refolding procedures and enhancing the enzyme's overall activity and stability.

With these benefits, the secretion system offers a promising solution to the challenges of endonuclease production, making it an attractive option for biologics manufacturers, vaccine developers, gene therapy companies, cell therapy producers, and contract development and manufacturing organizations (CDMOs) globally.